Lipid-lowering Drugs Market Size, Share, and Trends 2024 to 2033

Lipid-lowering Drugs Market Size and Companies

The global lipid-lowering drugs market size was valued at USD 33.12 billion in 2023 and is anticipated to reach around USD 46.58 billion by 2033, growing at a CAGR of 3.47% from 2024 to 2033. The rising cases of cardiovascular diseases across the globe is observed to drive the growth of the market.

Lipid-lowering Drugs Market Key Takeaways

• North America led the lipid-lowering drugs market with the largest market size in 2023.
• Asia Pacific is expected to witness the fastest growth in the market during the forecast period.
• By drug class, the statins and combinations segment dominated the market with the highest market share in 2023.
• By indication, the hypercholesterolemia segment projected the highest growth in the market in 2023.
• By distribution channel, the retail pharmacies segment dominated the market with the largest share in 2023.

Lipid-lowering Drugs Market Overview

Lipid-lowering drugs in the treatment of the serum lipids which are used in the treatment of cholesterol or lipoprotein. Lipoprotein is the kind of protein that binds fats like triglycerides and lipids in the blood. Lipid-lowering drugs are used to the risk of atherosclerotic cardiovascular disease (ASCVD). The rising prevalence of chronic diseases such as cardiovascular diseases and cardiovascular diseases is one of the leading causes of mortality in many countries. The rising cholesterol level is the major cause of heart-related diseases which drive the demand for effective drug treatment that drives the growth of the lipid-lowering drugs market.

Growth Factors

• The rising geriatric population the increasing awareness about health and the surging investments in healthcare by the people are driving the lipid-lowering drugs market.
• The risk associated with cardiovascular diseases and the prevalence of heart attacks due to the rising level of cholesterol in the body drives the demand for the effective drug or the treatment that drives the growth of the market.
• The rising investments in healthcare industry and the research and development activities in the innovations promotes the expansion of the market.
• The rising urbanization and changing lifestyles, eating and sleeping habits, and higher consumption of alcohol and smoking are negatively impacting the overall health of the humans which makes it more likely to get chronic diseases such as cardiovascular diseases that fuel the demand for lipid-lowering drugs market.
• The increasing consumption of junk food and acceptance of the sedentary lifestyle leads to a higher chance of getting higher cholesterol level which lead to higher chances of getting cardiovascular diseases drives the growth of the lipid-lowering drugs market.

Lipid-lowering Drugs Market Scope

Lipid-lowering Drugs Market Dynamics

Driver: Rising incidence of cardiovascular disease

Cardiovascular disease often arises from underlying conditions such as hyperlipidemia, characterized by elevated levels of cholesterol and triglycerides in the blood. As the global population faces increasing rates of obesity, sedentary lifestyles, and unhealthy dietary habits, the prevalence of hyperlipidemia and its associated cardiovascular risks continues to rise. This trend creates a growing demand for lipid-lowering drugs to manage lipid levels and reduce the risk of cardiovascular events. With global aging populations, there is an increased prevalence of cardiovascular risk factors such as hypertension, diabetes, and dyslipidemia.

Older adults are more susceptible to cardiovascular disease due to age-related changes in metabolism, hormone levels, and vascular function. Lipid-lowering drugs play a crucial role in managing lipid levels and reducing cardiovascular risks in elderly patients, contributing to their widespread use and the growth of the lipid-lowering drugs market.

Restraint: High cost of drugs

Lipid-lowering drugs, particularly newer medications and combination therapies, can be expensive. The high cost of treatment may limit access to these drugs for some patients, especially those without adequate insurance coverage or financial resources, thus hindering market expansion. The lipid-lowering drugs market faces competition from generic alternatives, particularly for older medications like statins. Generic drugs are often more affordable than brand-name counterparts, leading to pricing pressures and reduced market share for branded lipid-lowering drugs.

Opportunity: Advancements in lipid-lowering drugs

Advancements in lipid-lowering drugs and the rising investments in the launch of new cholesterol-lowering drugs bring several potential opportunities to the lipid-lowering drugs market. The advancements in PCSK9 inhibitors are a new class of drug that helps in lowering the cholesterol level in the blood. Additionally, rising investments in the healthcare sector and the development of drugs are contributing to the expansion of the market. The rising prevalence of cardiovascular diseases is driving the demand for the result-oriented drug class and the increasing research and development activities for the innovation and the launch of the latest drugs that contribute to the growth of the lipid-lowering drugs market.

Drug Insights

The statins and combinations segment dominated the lipid-lowering drugs market with the highest market share in 2023. The growth of the segment is attributed to the higher adoption of statins due to its higher cholesterol-lowering capacities. Statins are considered the best drug for cholesterol-lowering. It is the first drug to be given by physicians to patients with higher cholesterol levels. Statins are used to decrease cholesterol by blocking enzymes named the HMG-CoA reductase which the liver uses for the making of cholesterol. The statins and combination help decrease swelling and inflammation in the blood vessels and the lining of blood vessels, it helps reduce risks of blood clotting by stopping platelets from sticking together. All these advantages of statins help in the prevention of cardiovascular disease.

The cholesterol absorption inhibitors segment is observed to grow at a notable rate in the lipid-lowering drugs market. Cholesterol absorption inhibitors have been approved for use in various patient populations and clinical scenarios. In addition to primary hypercholesterolemia, these drugs are indicated for familial hypercholesterolemia, homozygous familial hypercholesterolemia, and mixed hyperlipidemia, broadening their market potential and adoption among healthcare providers. The availability of cholesterol absorption inhibitors for a range of lipid disorders enhances their relevance and usage in clinical practice.

Indication Insights

The hypercholesterolemia segment held the largest share of the lipid-lowering drugs market in 2023. The rising prevalence of hypercholesterolemia in the population is due to the changing lifestyle, diet, and also genetics that drive the demand for lipid-lowering drugs. Hypercholesterolemia is a disease caused by the increased level of cholesterol level. Hypercholesterolemia is caused by some of the inherited conditions abetalipoproteinemia (ABL), familial hypobetalipoproteinemia (FHBL), and chylomicron retention disease, aka Anderson’s disease.

Most of the hypercholesterolemia conditions are inherited or genetically. Moreover, the rising rate of research and development along with the approval of drugs utilized for hypercholesterolemia acts as a major driver for the segment to grow. Several lipid-lowering drugs have potential benefits on hypercholesterolemia by including plaque stabilization.

The coronary artery diseases segment is observed to grow at a considerable rate during the forecast period. Coronary artery disease is one of the leading causes of morbidity and mortality worldwide, particularly in developed countries. The rising incidence of CAD, fueled by factors such as sedentary lifestyles, unhealthy diets, obesity, and aging populations, drives the demand for lipid-lowering drugs as a key component of CAD management and prevention strategies.

Distribution Channel Insights

The retail pharmacies segment dominated the lipid-lowering drugs market in 2023. The dominance of the segment is attributed to the higher preference towards retail pharmacies for buying lipid-lowering drugs or any type of drugs due to the easy access and availability of drugs. The higher availability of retail pharmacies and the availability of the number of drugs are driving the expansion of the market. The variety and the discounts offered by the retail pharmacies are contributing to the growth of the segment.

The online pharmacies segment is observed to witness a notable rate of growth during the forecast period. Online pharmacies offer convenient access to a wide range of lipid-lowering drugs, allowing patients to purchase medications from the comfort of their homes and have them delivered directly to their doorstep. This convenience eliminates the need for in-person visits to traditional brick-and-mortar pharmacies, particularly for individuals with mobility issues, busy schedules, or limited access to transportation.

Regional Insights

North America led the lipid-lowering drugs market with the largest market share in 2023. The dominance of the market is attributed to the rising prevalence of cardiovascular diseases and the higher demand for drugs for the treatment for cardiovascular diseases. The population in North American countries is observed to have a sedentary lifestyle that increases the chances or risk of cholesterol-associated problems which directly contributes to the higher demand for lipid-lowering drugs.

Additionally, the well-developed healthcare infrastructure and the increasing investments in research and development activities in the innovation and development of the latest drug for heart-related risks are further propelling the growth of the lipid-lowering drugs market.

Asia Pacific is expected to witness the fastest growth in the lipid-lowering drugs market during the forecast period. The growth of the market in the region is expected to rise due to the rising number of the geriatric population which is more prone to get into cardiovascular diseases due to the age factor, and higher cholesterol levels. The rising number of heart attack rates in countries like India, and China due to the rising adoption of the sedentary lifestyle that is harmful to human health is causing the increased cholesterol level that drives the number of cardiovascular diseases in people and drives the demand for the market. The rising investment in pharmaceutical companies for the development of treatment drugs is driving the growth of the lipid-lowering drugs market in the region.

Lipid-lowering Drugs Market Recent Developments

• In April 2024, the Indian pharmaceutical industry announced to launch an innovative cholesterol-lowering injection that aims to help in decreasing the bad level of cholesterol of LDL in the blood and also decreases heart disease risks such as heart stroke and attacks.
• In April 2024, researchers of the Department of Biological Sciences and Bioengineering at the Technology Kanpur (IITK) launched the latest information about how cholesterol-lowering drugs such as Niacin work on the molecular level.
• In April 2024, Amarin (NASDAQ: AMRN) Corporation plc showcased two data presentations at ACC.24 which describe the impacts of VASCEPA ®/VAZKEPA ® on decreasing adverse cardiovascular events in patients with reduced lipoprotein level or baseline high and decreases the risks of cardiovascular diseases.
• In January 2022, Acuitas Therapeutics came in collaboration with Pfizer Inc. The company is working on the development of lipid nanoparticle (LNP) delivery systems for introducing messenger RNA (mRNA)-based therapeutics.
• In July 2023, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio® (inclisiran)’s label update for allowing the use in patients with the higher LDL-C which increases the risk of heart disease. This patient population consists of comorbidities such as diabetes and hypertension.

Lipid-lowering Drugs Market Companies

• Sanofi
• Pfizer, Inc.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• AbbVie, Inc.
• Viatris (Mylan N.V.)
• AstraZeneca PLC
• Dr. Reddy’s Laboratories Ltd.

Segments Covered in the Report

By Drug

• Statins & Combination
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• Fibrates
• Cholesterol Absorption Inhibitors
• Others

By Indication

• Hypercholesterolemia
• Coronary Artery Disease
• High Triglycerides

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa